Brought to you by 
Luitpold Pharmaceuticals sells nasal spray Sprix to Egalet
03 Feb 2023
Executive Summary
Daiichi Sankyo Co. Ltd.'s Luitpold Pharmaceuticals Inc. sold Egalet Corp. its marketed Sprix (ketorolac) nasal spray, indicated for short-term moderate-to-severe pain. Egalet paid $7mm, which is subject to change based on the amount of finished goods inventory. The transaction includes all IP and other related assets and liabilities.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Luitpold Pharmaceuticals sells nasal spray Sprix to Egalet
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice